MediciNova, Inc.

NASDAQ:MNOV

Biotechnology

Healthcare
$1.33 -1.32%

-$0.02 today

Market cap
$68.14M
Beta
0.62
P/E (TTM)
-5.6
EPS (TTM)
-$0.24
52W Low $1.17High $1.96

Volume 0.12M

Average 0.04M

MNOV Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

MediciNova, Inc.NASDAQ: MNOV

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $1.26B rose 72466.5% year over year, ahead of the +18127.2% change in trailing-twelve-month research & development. Sequentially, it rose 74586.3% from the prior quarter. Over 3 fiscal years it compounded at -7.8% a year.

Context

  • Research & development amounted to 1746.5% of revenue in FY2025.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +72466.5% holds above the trailing-twelve-month pace of +18127.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.26B+74586.3% QoQ
Last fiscal yearDec 2025
$7.15M-0.6% YoY
LTMMar 2026
$1.27B+18127.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+72466.5%——
1 year-0.6%——
3-year CAGR-7.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
7.15M USD
Year-over-year change
-0.6%
4-year CAGR
-3.1%

Research & Development vs competitors

How MNOV compares with its peers on the latest reported figures

  • MNOV's LTM Mar 2026 research & development of $1.27B is the highest of the 11 companies compared; the peer median is $53.93M.
  • Its year-over-year change of +18127.2% is the highest of 11, against a peer median of -8.6%.
  • Research & development amounts to 212494.0% of revenue for MNOV, versus a peer median of 518.8%.
MNOV Competitors Peer median
Research & Development for MNOV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNOVMediciNova, Inc.LTM Mar 2026$1.27B +18127.2%-7.8%212494.0%
VXRTVaxart, Inc.LTM Mar 2026$200.25M +133.0%+35.5%78.3%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M -5.4%+24.0%1163.2%
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$67.7M +8.5%+10.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
CBUSCibus, Inc.LTM Mar 2026$41.12M -18.1%+56.4%959.3%
XBITXBiotech Inc.LTM Mar 2026$40.98M +3.6%+14.5%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M -48.6%-81.3%—
FBIOFortress Biotech, Inc.LTM Mar 2026$8.51M -76.4%-55.5%12.9%
Peer median (excluding MNOV) $53.93M-8.6%+12.6%518.8%

Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.04M01M0409.66K
Cost of Revenue0000378.61K
Gross Profit4.04M01M031.05K
Gross Margin100.0%—100.0%—7.6%
Research & Development8.1M9.14M5.66M7.2M7.15M
Selling, General & Admin5.72M5.48M5.24M5.48M6.16M
Operating Expenses14.25M14.63M10.9M12.68M13.31M
Depreciation & Amortization26.15K17.71K20.3K21.08K20.1K
EBITDA(10.11M)(14.05M)(8.55M)(11.02M)(11.97M)
EBITDA Margin-250.3%—-854.8%—-2922.4%
Operating Income(10.22M)(14.63M)(9.9M)(12.68M)(13.28M)
Operating Margin-253.0%—-990.0%—-3242.5%
Interest Income143.63K809.67K1.83M1.67M1.3M
Interest Expense00000
Other Income / Expenses84.13K562.39K1.33M1.63M1.29M
Income Before Tax(10.13M)(14.07M)(8.57M)(11.04M)(11.99M)
Pre-Tax Margin-250.9%—-856.8%—-2927.3%
Income Tax Expense2.57K2.82K3.05K5.54K5.99K
Net Income(10.13M)(14.07M)(8.57M)(11.05M)(12M)
Net Margin-251.0%—-857.2%—-2928.8%
EPS (Basic)(0.21)(0.29)(0.17)(0.23)(0.24)
EPS (Diluted)(0.21)(0.29)(0.17)(0.23)(0.24)
Weighted Avg Shares48.6M49.05M49.05M49.05M49.06M
Weighted Avg Shares (Diluted)48.6M49.05M49.05M49.05M49.06M

MediciNova, Inc.

NASDAQ:MNOV

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.